Antivirals / External Use / Immunological agents / Immunostimulating

VIFERON® 1 000 000 IU, 10 suppositories

Brands: Feron (Russia)

$34.30

Quantity

VIFERON® 1 000 000 IU, 10 suppositories quantity

Add to cart

Add to wishlist

Sku:

e02a52a63e17

Brands:: Feron (Russia)

Description

Composition

One suppository contains

• Active substance – interferon alpha-2b human recombinant 150,000 IU, 500,000 IU, 1,000,000 IU, 3,000,000 IU,
• Excipients: ascorbic acid, sodium ascorbate, alpha-tocopherol acetate, disodium edetate dihydrate, polysorbate-80, cocoa butter, confectionery fat or cocoa butter substitute.

Pharmacological properties

Pharmacokinetics

Rectal use of the drug VIFERON® promotes a longer circulation of interferon in the blood than with intravenous or intramuscular administration of human recombinant interferon alfa-2b.

A decrease in the level of serum interferon 12 hours after the administration of VIFERON® necessitates its repeated administration.

An analysis of the dynamics of the content of endogenous interferon in premature newborns with a gestational age of less than 34 weeks indicates the need to administer the drug VIFERON® 3 times a day after 8 hours.

Pharmacodynamics

Interferon alpha-2b human recombinant has pronounced antiviral, antiproliferative and immunomodulatory properties.

The complex composition of the drug causes a number of new effects:
in the presence of ascorbic acid and tocopherol acetate, the specific antiviral activity of human recombinant interferon alpha-2b increases, its immunomodulatory effect on T- and B-lymphocytes increases, the level of
immunoglobulin E normalizes, the functioning of the endogenous interferon system is restored, there are no side effects that occur with parenteral administration of interferon preparations. It has been established that when using the drug VIFERON®
for 2 years, antibodies are not formed that neutralize the antiviral activity of interferon alpha-2b human recombinant, the functioning of the endogenous interferon system is normalized.

Indications for use

• infectious and inflammatory diseases in newborns, including premature babies (as part of complex therapy) acute respiratory viral infections (ARVI), pneumonia (bacterial, viral, chlamydial), meningitis, sepsis, specific intrauterine infection (chlamydia, herpes, cytomegaly, enterovirus infection, visceral candidiasis, mycoplasmosis)
• chronic viral hepatitis B, C, D in children and adults (as part of complex therapy), as well as in combination with viferon therapy
  using plasmapheresis and hemosorption of chronic viral hepatitis of a pronounced degree of activity and cirrhosis of the liver
• urogenital infection in pregnant women (chlamydia, genital herpes, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) as an interferon-correcting agent
• influenza and other acute respiratory viral diseases, including those complicated by bacterial infections in adults (as part of complex therapy)

Dosage and administration

The drug is used rectally.

Children under 7 years old are prescribed VIFERON® 150,000 IU, children over 7 years old and adults – VIFERON® 500,000 IU.

VIFERON® 1000000 IU, VIFERON® 3000000 IU are prescribed primarily for the treatment of viral hepatitis in children and adults.

In the complex therapy of various infectious and inflammatory diseases in newborns, including premature babies

Newborn children VIFERON® 150,000 IU are prescribed
1 suppository 2 times a day after 12 hours. The course of treatment is 5 days.

The recommended number of courses for various
infectious and inflammatory diseases in newborns
, including premature ones:

ARVI – 1 course, pneumonia (bacterial – 1-2 courses, viral – 1 course, chlamydial – 1 course), sepsis – 2-3 courses, meningitis – 1-2 courses, herpes infection – 2 courses, enterovirus infection – 1- 2 courses, cytomegalovirus infection – 2-3 courses, mycoplasmosis – 2-3 courses.

The break between courses is 5 days.

For premature newborns with a gestational age of less than 34 weeks, VIFERON® 150,000 IU is prescribed 1 suppository 3 times
a day after 8 hours. The course of treatment is 5 days.

In the complex therapy of chronic viral hepatitis B, C, D in children and adults, as well as in combination with viferon therapy using plasmapheresis and hemosorption of chronic viral hepatitis of a pronounced degree of activity and liver cirrhosis

For children with chronic viral hepatitis, the drug is prescribed
in the following age dosages:

up to 6 months daily dose of 300,000 IU,

from 6 to 12 months – 500,000 IU-1,000,000 IU (depending on height and weight),

from 1 year to 3 years – 1000000 IU-2000000 IU,

from 3 to 7 years – 2000000 IU-3000000 IU,

older than 7 years – 4000000 IU-5000000 IU.

In the morning and in the evening it is possible to use different dosages, for example: morning – 1 million IU, at night 500 thousand IU. The drug is used 2 times a day after 12 hours for the first 10 days daily, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters. Children with chronic viral hepatitis of a pronounced degree of activity and cirrhosis of the liver before plasmapheresis and / or hemosorption are shown to use the drug for 14 days daily, 1 suppository 2 times a day after 12 hours (children under 7 years old VIFERON® 150,000 IU, children over 7 years old – VIFERON® 500000 IU).

Adults with chronic viral hepatitis are prescribed
VIFERON® 3,000,000 IU, 1 suppository 2 times a day after
12 hours for 10 days daily, then three times a week every other day
for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.

As an interferon-correcting agent in pregnant women
with urogenital infection (chlamydia, genital herpes, cytomegalovirus infection, ureaplasmosis, trichomoniasis, bacterial vaginosis, human papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis)

In the complex therapy of pregnant women with urogenital infection from 28 to 34 weeks of gestation, VIFERON® 150,000 IU is used 1 suppository 2 times a day 12 hours a day (10 suppositories per course). From 35 weeks before delivery, VIFERON® 500,000 IU is used daily, 1 suppository 2 times a day after 12 hours for 5 days.

A total of 7 courses for 12 weeks, starting from the 28th week of gestation, a break between courses is 7 days. The duration of treatment is determined by clinical efficacy and laboratory parameters.

In the complex therapy of influenza and other acute respiratory viral diseases, including those complicated by a bacterial infection in adults

Apply VIFERON® 500000 IU 1 suppository 2 times a day every 12 hours every day. The course of treatment is 5 days.

Side effects

Rarely – allergic reactions (skin rashes and itching). These phenomena are reversible and disappear 72 hours after discontinuation of the drug.

Contraindications

– hypersensitivity to the active ingredient or excipients

– gestation period up to 28 weeks

Drug Interactions

VIFERON® is compatible and well combined with all drugs used in the treatment of these diseases (antibiotics, chemotherapy drugs, glucocorticosteroids, immunosuppressants).

Special instructions

Pregnancy and lactation

The drug is approved for use from the 28th week of pregnancy.

It has no restrictions for use during lactation.

Features of the influence of the drug on the ability to drive a vehicle or potentially dangerous mechanisms

No influence of human recombinant interferon alfa-2b in the form of suppositories (VIFERON®) on the ability to drive a vehicle or potentially dangerous mechanisms was found.

Overdose

Cases of overdose are not registered.

Storage conditions

Store between 2°C and 8°C, protected from light. Keep out of the reach of children!

Shelf life – 2 years

Do not use the drug after the expiration date.

Additional information